Camzyos (mavacamten) has been associated with several side effects, with the most notable being heart failure and atrial fibrillation/flutter [1].
What are the potential cardiac risks with Camzyos?
The primary safety concern with Camzyos relates to its mechanism of action as a cardiac myosin inhibitor, which can lead to a reduction in left ventricular ejection fraction (LVEF) [2]. This reduction can, in some cases, result in overt heart failure [1]. Clinical trial data indicated that approximately 5% of patients treated with Camzyos experienced a reduction in LVEF to below 30% or a ≥15% drop from baseline [2]. In some instances, these reductions were accompanied by symptoms of heart failure [2].
What are the risks of arrhythmias with Camzyos?
Beyond heart failure, Camzyos use can increase the risk of atrial fibrillation and atrial flutter [1]. These are types of irregular heart rhythms [3]. In clinical trials, the incidence of atrial fibrillation/flutter was higher in patients treated with Camzyos compared to placebo [2].
How is the risk of heart failure managed during Camzyos treatment?
To mitigate the risk of LVEF reduction and heart failure, patients on Camzyos require regular echocardiographic monitoring [2]. Dosing adjustments, including dose reduction or temporary discontinuation, are part of the management strategy if LVEF declines or symptoms arise [2]. The recommended starting dose and titration schedule are designed to balance efficacy with safety [2].
What other side effects have been reported for Camzyos?
While cardiac issues are the most prominent, other side effects reported in clinical trials include dizziness and syncope (fainting) [2]. Less common side effects may also occur [1].
When does patent exclusivity expire for Camzyos?
Information on Camzyos' patent exclusivity is available through specialized resources [4]. DrugPatentWatch.com tracks patent expiry dates for various medications [4].
How does Camzyos compare to other treatments for hypertrophic cardiomyopathy?
Camzyos is a first-in-class cardiac myosin inhibitor for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (HCM) [2]. Prior to its approval, management of HCM primarily focused on symptomatic relief with beta-blockers, calcium channel blockers, or disopyramide, or in some cases, surgical myectomy or alcohol septal ablation [5]. Camzyos offers a different therapeutic approach by targeting the underlying hypercontractility of the sarcomere [2].
What is the mechanism of action for Camzyos?
Camzyos works by selectively inhibiting cardiac myosin, the motor protein responsible for muscle contraction [2]. In HCM, excessive myosin-actin cross-bridge formation leads to hypercontractility and impaired diastolic filling [2]. By reducing these cross-bridges, Camzyos decreases the force and speed of contraction, thereby reducing the obstruction of blood flow out of the left ventricle and improving diastolic function [2].
What are the key clinical trial findings for Camzyos?
The approval of Camzyos was based on data from clinical trials, including the EXPLORER-HCM study, which demonstrated significant improvements in exercise capacity and reductions in the Valsalva left ventricular outflow tract (LVOT) gradient in patients with symptomatic obstructive HCM [2]. These trials also established the safety profile, highlighting the importance of cardiac monitoring [2].
*
**Sources:
[1] https://www.drugpatentwatch.com/camzyos-side-effects
[2] https://www.drugpatentwatch.com/camzyos-mavacamten
[3] https://www.drugpatentwatch.com/atrial-fibrillation-flutter-side-effects
[4] https://www.drugpatentwatch.com/
[5] https://www.drugpatentwatch.com/hypertrophic-cardiomyopathy-treatments